Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
P/B ratio for Amylyx Pharmaceuticals, Inc. (AMLX)
P/B ratio as of 2023: 2.28
According to Amylyx Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.28. At the end of 2022 the company had a P/B ratio of 7.22.
P/B ratio history for Amylyx Pharmaceuticals, Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 2.28 |
| 2022 | 7.22 |
| 2021 | -6.92 |
| 2020 | -15.29 |
| 2019 | -40.24 |